Nyxoah (NASDAQ:NYXH) Announces Earnings Results, Beats Expectations By $0.04 EPS

Posted by Stanley Muller on Nov 8th, 2026

Nyxoah (NASDAQ:NYXH – Get Free Report) released its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04, FiscalAI reports. The firm had revenue of $10.39 million during the quarter, compared to analysts’ expectations of $11.00 million. Nyxoah had a negative net margin of 313.03% and a negative return on equity of 162.01%.

Here are the key takeaways from Nyxoah’s conference call:

Nyxoah cut its 2026 revenue guidance to €33 million–€35 million, citing a U.S. launch ramp more in line with historical adoption patterns, despite strong sequential growth in the quarter.
U.S. revenue rose 29% sequentially to €6.7 million, while the company trained 80 surgeons and activated 53 accounts in Q3; it plans to prioritize deeper utilization at existing accounts.
The ACCCESS study met its primary efficacy and safety endpoints in patients with complete concentric collapse (CCC), and Nyxoah submitted an FDA supplement seeking to expand Genio’s U.S. indication to this group, which the company estimates represents about one in four patients evaluated for the therapy.
Gross margin improved to 63.1% from 60.5% a year earlier, and the company reported a narrower operating loss. It also cited higher 2027 CMS facility reimbursement rates for Genio procedures.
Cash and financial assets fell to €77.1 million at September 30 from €97.8 million at June 30, underscoring the company’s ongoing cash use as it invests in its commercial launch.

Nyxoah Trading Up 4.3%

NYXH stock traded up $0.03 on Friday, hitting $0.85. 262,088 shares of the company were exchanged, compared to its average volume of 255,984. Nyxoah has a twelve month low of $0.80 and a twelve month high of $5.92. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31. The business’s fifty day moving average is $1.27 and its two-hundred day moving average is $2.42. The stock has a market capitalization of $32.78 million, a price-to-earnings ratio of -0.43 and a beta of 1.80.

Wall Street Analysts Forecast Growth

NYXH has been the topic of a number of recent analyst reports. Raymond James Financial set a $3.00 price target on Nyxoah in a research note on Tuesday, October 27th. Cantor Fitzgerald lowered their price objective on Nyxoah to $3.00 and set an “overweight” rating for the company in a research report on Tuesday, October 27th. Wall Street Zen upgraded Nyxoah from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Finally, Robert W. Baird set a $2.31 price target on Nyxoah in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.55.

View Our Latest Stock Report on Nyxoah

About Nyxoah

(Get Free Report)

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.

Nyxoah (NASDAQ:NYXH) Announces Earnings Results, Beats Expectations By $0.04 EPS

Nyxoah Trading Up 4.3%

Wall Street Analysts Forecast Growth

About Nyxoah

See Also

You might be interested in: